Fig. 2.

Attitudes toward enrolling in a phase 1 clinical trial for fetal enzyme replacement therapy. Respondents were asked the question “If you or your partner were to become pregnant and the fetus were diagnosed with MPS, how likely would you be to enroll in a phase I clinical trial (to determine safety) for fetal enzyme replacement therapy?” A all respondents (n = 188), B Comparison of respondents from the United States (n = 115) and the United Kingdom (n = 34) (p = 0.58, Fisher’s exact test), C Variables with statistical significance on univariate and multivariable regression. Or odds ratio, CI confidence interval, ERT enzyme replacement therapy